Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma.

Trial Profile

Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing vascular response using DCE-MRI to predict the efficacy of axitinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top